CD274 and thymoma: Studies have shown that PD‐1/PD‐L1 is highly expressed in 82% of thymic epithelial tumors and is more highly expressed in the more aggressive types of B2 and B3 thymomas and thymic cancers, suggesting that ICIs may have an advantage in immunotherapy for thymic epithelial tumors with higher malignancies [3].